ERBB2 and breast carcinoma: The prevalence of the positive immunomarkers was consistent with what is usual in breast cancer: 100% of the samples were Ki-67 and GATA 3 positive; 94.4% were BerEP4 positive; 83.3% were E-cadherin and ER positive; CK7 and PR occurred at 72.2% and 55.5%, respectively; 16.6% of the samples were HER2 and P40; and 11.1% were CK5 positive.